Download Now: 7 Unstoppable Growth Engines of India's $10 Trillion Bull Run...
Here is the latest financial fact sheet of PARMAX PHARMA. For more details, see the PARMAX PHARMA quarterly results and PARMAX PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 1.7 |
No. of shares | m | 3.74 |
1 Week | % | -5.4 |
1 Month | % | 3.0 |
1 Year | % | -0.7 |
52 week H/L | Rs | 36.6/24.2 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
PARMAX PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 21 | 20 | 52 | 82 | 58 | |
Low | Rs | 17 | 16 | 15 | 33 | 26 | |
Sales per share (Unadj.) | Rs | 23.5 | 41.0 | 51.3 | 35.8 | 30.2 | |
Earnings per share (Unadj.) | Rs | 0.2 | 0.8 | 1.5 | 0.3 | -0.2 | |
Diluted earnings per share | Rs | 0.2 | 1.1 | 2.0 | 0.4 | -0.3 | |
Cash flow per share (Unadj.) | Rs | 2.2 | 2.8 | 5.3 | 4.1 | 3.5 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 9.1 | 9.9 | 11.4 | 11.7 | 11.5 | |
Adj. book value per share | Rs | 12.4 | 13.5 | 15.6 | 15.9 | 15.7 | |
Shares outstanding (eoy) | m | 5.10 | 5.10 | 5.10 | 5.10 | 5.10 | |
Price / Sales ratio | x | 0.8 | 0.4 | 0.7 | 1.6 | 1.4 | |
Avg P/E ratio | x | 124.8 | 21.4 | 22.7 | 207.3 | -205.9 | |
P/CF ratio (eoy) | x | 8.9 | 6.4 | 6.4 | 14.1 | 12.1 | |
Price / Book Value ratio | x | 2.1 | 1.8 | 2.9 | 4.9 | 3.7 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 98 | 92 | 172 | 293 | 214 | |
Total wages/salary | Rs m | 21 | 29 | 36 | 35 | 28 |
PARMAX PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 120 | 209 | 262 | 182 | 154 | |
Other income | Rs m | 0 | 1 | 1 | 1 | 0 | |
Total revenues | Rs m | 120 | 210 | 262 | 183 | 154 | |
Gross profit | Rs m | 11 | 18 | 34 | 26 | 23 | |
Depreciation | Rs m | 10 | 10 | 19 | 19 | 19 | |
Interest | Rs m | 0 | 1 | 4 | 4 | 4 | |
Profit before tax | Rs m | 1 | 7 | 12 | 3 | 0 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 0 | 3 | 5 | 2 | 2 | |
Profit after tax | Rs m | 1 | 4 | 8 | 1 | -1 | |
Gross profit margin | % | 9.3 | 8.5 | 13.1 | 14.0 | 14.7 | |
Effective tax rate | % | 19.8 | 41.3 | 37.6 | 53.4 | 326.5 | |
Net profit margin | % | 0.7 | 2.1 | 2.9 | 0.8 | -0.7 |
PARMAX PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 90 | 94 | 103 | 66 | 75 | |
Current liabilities | Rs m | 98 | 109 | 112 | 73 | 71 | |
Net working cap to sales | % | -6.5 | -6.9 | -3.5 | -4.1 | 2.6 | |
Current ratio | x | 0.9 | 0.9 | 0.9 | 0.9 | 1.1 | |
Inventory Days | Days | 11 | 7 | 5 | 4 | 4 | |
Debtors Days | Days | 34,925,094 | 57,695,789 | 23,089,062 | 135,498 | 147,800 | |
Net fixed assets | Rs m | 86 | 100 | 112 | 106 | 97 | |
Share capital | Rs m | 45 | 45 | 45 | 45 | 45 | |
"Free" reserves | Rs m | 2 | 6 | 14 | 15 | 14 | |
Net worth | Rs m | 46 | 51 | 58 | 60 | 59 | |
Long term debt | Rs m | 53 | 50 | 54 | 45 | 45 | |
Total assets | Rs m | 196 | 211 | 227 | 180 | 176 | |
Interest coverage | x | 4.0 | 6.6 | 4.4 | 1.8 | 1.1 | |
Debt to equity ratio | x | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | |
Sales to assets ratio | x | 0.6 | 1.0 | 1.2 | 1.0 | 0.9 | |
Return on assets | % | 0.6 | 2.7 | 4.9 | 2.9 | 1.5 | |
Return on equity | % | 1.7 | 8.5 | 13.0 | 2.4 | -1.8 | |
Return on capital | % | 1.3 | 8.5 | 13.9 | 6.6 | 4.0 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx outflow | Rs m | 0 | 1 | 4 | 0 | 0 | |
Net fx | Rs m | -0 | -1 | -4 | 0 | 0 |
PARMAX PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 9 | 28 | 35 | 7 | 3 | |
From Investments | Rs m | -34 | -24 | -31 | -15 | -9 | |
From Financial Activity | Rs m | 31 | -2 | 4 | -9 | -0 | |
Net Cashflow | Rs m | 6 | 2 | 8 | -17 | -6 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Alkesh M Gopani | COMP SEC: Yash Vora | YEAR OF INC: 1994 | BSE CODE: 540359 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
Compare PARMAX PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.